Amgen Financial Ratios
NASDAQ: AMGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amgen ratio analysis
Amgen earned a net margin of 21.0% in FY 2025, up from 12.2% a year earlier. Gross margin was 67.2% compared with a median of 75.8% over the prior 9 years. Return on equity reached 89.1%, meaning Amgen generated 0.89 dollars of profit for every dollar of shareholders' equity, an unusually high figure that often reflects a small equity base after share buybacks.
Debt-to-equity stood at 6.31 versus 10.23 the year before, and the current ratio was 1.14. At the end of FY 2025, AMGN traded at 23.0 times earnings; across the 10 fiscal years shown, its year-end P/E ranged from 14.3 to 64.6, with a median of 21.8. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Amgen financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 23.02 | 34.55 | 23.06 | 21.69 | 21.88 | 18.68 | 18.51 | 15.49 | 64.65 | 14.28 |
| Price / sales | 4.80 | 4.20 | 5.47 | 5.37 | 4.94 | 5.30 | 6.18 | 5.44 | 5.56 | 4.76 |
| Price / book | 20.36 | 23.87 | 24.73 | 38.60 | 19.14 | 14.32 | 14.92 | 10.33 | 5.04 | 3.66 |
| Gross margin | 67.2% | 61.5% | 70.0% | 75.7% | 75.2% | 75.8% | 81.4% | 82.7% | 82.2% | 81.9% |
| Operating margin | 24.7% | 21.7% | 28.0% | 36.3% | 29.4% | 35.9% | 41.4% | 43.2% | 43.6% | 42.6% |
| Net margin | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% | 28.6% | 33.6% | 35.3% | 8.7% | 33.6% |
| Free cash flow margin | 22.0% | 31.1% | 26.1% | 33.4% | 32.3% | 38.9% | 36.5% | 44.5% | 46.0% | 41.8% |
| Return on equity (ROE) | 89.1% | 69.6% | 107.8% | 179.0% | 88.0% | 77.2% | 81.1% | 67.2% | 7.8% | 25.8% |
| Return on assets (ROA) | 8.5% | 4.5% | 6.9% | 10.1% | 9.6% | 11.5% | 13.1% | 12.6% | 2.5% | 9.9% |
| Debt / equity | 6.31 | 10.23 | 10.37 | 10.64 | 4.97 | 3.51 | 3.09 | 2.71 | 1.40 | 1.16 |
| Current ratio | 1.14 | 1.26 | 1.65 | 1.41 | 1.59 | 1.81 | 1.44 | 2.79 | 5.49 | 4.11 |
| Revenue growth | 10.0% | 18.6% | 7.1% | 1.3% | 2.2% | 8.8% | -1.6% | 3.9% | -0.6% | 6.1% |
| EPS growth | 88.2% | -39.5% | 3.1% | 17.8% | -16.5% | -4.4% | 2.1% | 369.1% | -73.7% | 13.0% |